| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 22, 2022 |
| Accession Number: | 0000878526-22-000068 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue
Highlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry for app
PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS), (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domes
SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc
Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth. Earlier this year, the Board of Directors engaged a strategic consulting firm to assist it in developing a strategy to build upon Natus' market leading p
SAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou. "Route 92 Medical's technology offers uniquely disruptive solutions in the rapidly growing stroke treatment market. The company is well-positioned for long-term growth, continued product innovation, and meaningful improvements in patient outc
NEW YORK, July 21, 2022 /PRNewswire/ -- Novanta Inc. (NASD: NOVT) will replace Six Flags Entertainment Corp. (NYSE:SIX) in the S&P MidCap 400, and Six Flags will replace Natus Medical Inc. (NASD: NTUS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 26. ArchiMed acquired Natus Medical in a deal that closed today. Six Flags Entertainment is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 26, 2022 S&P MidCap 400 Addition Novanta NOVT Information Technology S&P MidCap 400
MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the "Company" or "Natus"), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed ("ArchiMed"), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive merger agreement, Natus shareholders received $33.50 in cash for each share of Natus common stock. "ArchiMed's mix of operational, medical, scientific and financial expertise will help us continue
15-12G - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
EFFECT - NATUS MEDICAL INC (0000878526) (Filer)
Novanta Inc (NASDAQ:NOVT) braces to replace Six Flags Entertainment Corp (NYSE:SIX) in the S&P MidCap 400 effective before trading on July 26. Six Flags will replace Natus Medical Inc (NASDAQ:NTUS) in the S&P SmallCap 600. ArchiMed snapped Natus Medical in a deal that closed today. Novanta clocked 26% revenue growth to $204.2 million in the first quarter of FY22, beating the consensus of $196.1 million. Adjusted EPS of $0.73 beat the consensus of $0.63. Price Action: NOVT shares traded higher by 9.74% at $150.25 in the premarket on the last check Friday.
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20220721-1454377/1454377_6ntus.pdf
Natus Medical (NASDAQ:NTUS) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.26 by 15.38 percent. This is a 37.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $119.80 million which beat the analyst consensus estimate of $115.70 million by 3.54 percent. This is a 4.24 percent increase over sales of $114.93 million the same period last year.
SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G - NATUS MEDICAL INC (0000878526) (Subject)
SC 13G/A - NATUS MEDICAL INC (0000878526) (Subject)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)
4 - NATUS MEDICAL INC (0000878526) (Issuer)